ADTX
Aditxt Inc

15,382
Mkt Cap
$1.95M
Volume
150,403.00
52W High
$11,941.28
52W Low
$3.48
PE Ratio
0.00
ADTX Fundamentals
Price
$2.87
Prev Close
$3.48
Open
$3.42
50D MA
$53.92
Beta
0.68
Avg. Volume
193,139.83
EPS (Annual)
-$346,053.46
P/B
-0.02
Rev/Employee
$5,153.27
Loading...
Loading...
News
all
press releases
Aditxt Provides Updates on its Growth Vision for bitXbio, Planned Digital Asset Treasury, Pearsantas Planned IPO, And Evofems Plan to Regain a National Listing
Aditxt, Inc. (Nasdaq: ADTX) (Aditxt or the Company), a social innovation platform accelerating promising health innovations, today shared its growth vision under the bitXbio strategy. bitXbio...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025
Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-113 reverse split of its...
Business Wire·22d ago
News Placeholder
Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market
Aditxt, Inc. (Nasdaq: ADTX) ('Aditxt' or the 'Company'), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ('Pearsanta...
Business Wire·24d ago
News Placeholder
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.
Stocktwits·9mo ago
News Placeholder
Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025
Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc...
Business Wire·9mo ago
News Placeholder
Microcap Biotech Aditxt Rallies Retail Interest Ahead Of CEO’s Fireside Chat: What’s On Investors’ Radar?
The event will cover Adimune, Inc., which focuses on autoimmunity treatments, and subsidiary Pearsanta's planned IPO in 2025.
Stocktwits·9mo ago
News Placeholder
Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time
Aditxt, Inc. (Aditxt or the Company) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced that it will host a virtual Fireside Chat on...
Business Wire·9mo ago
News Placeholder
Aditxts Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform
Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, is pleased to announce that its Board of Directors has...
Business Wire·10mo ago
News Placeholder
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Adimune, Inc. (Adimune...
Business Wire·11mo ago
News Placeholder
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 PR Newswire SAN DIEGO, Nov. 14, 2024 Improved...
PR Newswire·1y ago

Latest ADTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.